Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models.

Schuller AG, Barry ER, Jones RD, Henry RE, Frigault MM, Beran G, Linsenmayer D, Hattersley M, Smith A, Wilson J, Cairo S, Déas O, Nicolle D, Adam A, Zinda M, Reimer C, Fawell SE, Clark EA, D'Cruz CM.

Clin Cancer Res. 2015 Jun 15;21(12):2811-9. doi: 10.1158/1078-0432.CCR-14-2685. Epub 2015 Mar 16.

2.

Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.

Choueiri TK, Plimack E, Arkenau HT, Jonasch E, Heng DYC, Powles T, Frigault MM, Clark EA, Handzel AA, Gardner H, Morgan S, Albiges L, Pal SK.

J Clin Oncol. 2017 Sep 10;35(26):2993-3001. doi: 10.1200/JCO.2017.72.2967. Epub 2017 Jun 23.

PMID:
28644771
3.

Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models.

Ciamporcero E, Miles KM, Adelaiye R, Ramakrishnan S, Shen L, Ku S, Pizzimenti S, Sennino B, Barrera G, Pili R.

Mol Cancer Ther. 2015 Jan;14(1):101-10. doi: 10.1158/1535-7163.MCT-14-0094. Epub 2014 Nov 7.

4.

Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation.

Zhao H, Nolley R, Chan AMW, Rankin EB, Peehl DM.

Cancer Biol Ther. 2017 Nov 2;18(11):863-871. doi: 10.1080/15384047.2016.1219816. Epub 2016 Aug 11.

5.

Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays.

Srivastava AK, Hollingshead MG, Weiner J, Navas T, Evrard YA, Khin SA, Ji JJ, Zhang Y, Borgel S, Pfister TD, Kinders RJ, Bottaro DP, Linehan WM, Tomaszewski JE, Doroshow JH, Parchment RE.

Clin Cancer Res. 2016 Jul 15;22(14):3683-94. doi: 10.1158/1078-0432.CCR-15-2323. Epub 2016 Mar 21.

6.

Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model.

Surriga O, Rajasekhar VK, Ambrosini G, Dogan Y, Huang R, Schwartz GK.

Mol Cancer Ther. 2013 Dec;12(12):2817-26. doi: 10.1158/1535-7163.MCT-13-0499. Epub 2013 Oct 18.

7.

Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET.

Wu W, Bi C, Credille KM, Manro JR, Peek VL, Donoho GP, Yan L, Wijsman JA, Yan SB, Walgren RA.

Clin Cancer Res. 2013 Oct 15;19(20):5699-710. doi: 10.1158/1078-0432.CCR-13-1758. Epub 2013 Aug 29.

8.

Savolitinib Heads for Phase III Trial in PRCC.

[No authors listed]

Cancer Discov. 2017 Sep;7(9):OF4. doi: 10.1158/2159-8290.CD-NB2017-105. Epub 2017 Jul 19.

9.

Phenotypic drug screening and target validation for improved personalized therapy reveal the complexity of phenotype-genotype correlations in clear cell renal cell carcinoma.

Schneider M, Schüler J, Höfflin R, Korzeniewski N, Grüllich C, Roth W, Teber D, Hadaschik B, Pahernik S, Hohenfellner M, Duensing S.

Urol Oncol. 2014 Aug;32(6):877-84. doi: 10.1016/j.urolonc.2014.03.011. Epub 2014 Jun 11.

PMID:
24929890
10.

Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models.

Gavine PR, Ren Y, Han L, Lv J, Fan S, Zhang W, Xu W, Liu YJ, Zhang T, Fu H, Yu Y, Wang H, Xu S, Zhou F, Su X, Yin X, Xie L, Wang L, Qing W, Jiao L, Su W, Wang QM.

Mol Oncol. 2015 Jan;9(1):323-33. doi: 10.1016/j.molonc.2014.08.015. Epub 2014 Sep 10.

11.

Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models.

Yamazaki S, Vicini P, Shen Z, Zou HY, Lee J, Li Q, Christensen JG, Smith BJ, Shetty B.

J Pharmacol Exp Ther. 2012 Mar;340(3):549-57. doi: 10.1124/jpet.111.188870. Epub 2011 Nov 30.

12.

Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification.

Okamoto W, Okamoto I, Arao T, Kuwata K, Hatashita E, Yamaguchi H, Sakai K, Yanagihara K, Nishio K, Nakagawa K.

Mol Cancer Ther. 2012 Jul;11(7):1557-64. doi: 10.1158/1535-7163.MCT-11-0934. Epub 2012 Jun 22.

13.

Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling.

Matzke-Ogi A, Jannasch K, Shatirishvili M, Fuchs B, Chiblak S, Morton J, Tawk B, Lindner T, Sansom O, Alves F, Warth A, Schwager C, Mier W, Kleeff J, Ponta H, Abdollahi A, Orian-Rousseau V.

Gastroenterology. 2016 Feb;150(2):513-25.e10. doi: 10.1053/j.gastro.2015.10.020. Epub 2015 Oct 24.

PMID:
26597578
14.
15.
16.

Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.

Varkaris A, Corn PG, Parikh NU, Efstathiou E, Song JH, Lee YC, Aparicio A, Hoang AG, Gaur S, Thorpe L, Maity SN, Bar Eli M, Czerniak BA, Shao Y, Alauddin M, Lin SH, Logothetis CJ, Gallick GE.

Clin Cancer Res. 2016 Jan 1;22(1):107-21. doi: 10.1158/1078-0432.CCR-15-0235. Epub 2015 Aug 13.

17.

Savolitinib for MET-driven papillary renal cell carcinoma.

Gilbert JA.

Lancet Oncol. 2017 Aug;18(8):e440. doi: 10.1016/S1470-2045(17)30508-9. Epub 2017 Jun 29. No abstract available.

PMID:
28669737
18.

Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation.

Henry RE, Barry ER, Castriotta L, Ladd B, Markovets A, Beran G, Ren Y, Zhou F, Adam A, Zinda M, Reimer C, Qing W, Su W, Clark E, D'Cruz CM, Schuller AG.

Oncotarget. 2016 Sep 6;7(36):57651-57670. doi: 10.18632/oncotarget.10859.

19.

Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.

Ji F, Liu X, Wu Y, Fang X, Huang G.

Drug Des Devel Ther. 2015 Oct 19;9:5697-704. doi: 10.2147/DDDT.S89410. eCollection 2015.

20.

Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population.

Lindor NM, Dechet CB, Greene MH, Jenkins RB, Zincke MT, Weaver AL, Wilson M, Zincke H, Liu W.

Genet Test. 2001 Summer;5(2):101-6. Review.

PMID:
11551094

Supplemental Content

Support Center